A new initiative at Princess Margaret Cancer Centre in Ontario aims to screen up to 100,000 individuals over the next five years for genetic conditions linked to hereditary cancers and high cholesterol-heart disease risks. This project, considered one of Canada’s most extensive population genomics studies, enables participants and healthcare providers to make informed decisions to potentially prevent, reduce, or delay cancer and heart disease. Simultaneously, researchers at the hospital gain valuable data to help address individuals with heightened health risks.
The initial phase targets cancer patients at the hospital, especially those with potential genetic predispositions that could impact their treatment plans and monitoring protocols, according to Dr. Raymond Kim, the medical director of cancer early detection at Princess Margaret. Understanding the genetic makeup of these patients allows healthcare professionals to assess additional cancer risks and tailor treatment strategies accordingly.
One such patient, Leslie Born, discovered she carried a BRCA2 genetic mutation following her cancer diagnosis. This mutation significantly increases the risk of various cancers, prompting Born to undergo regular breast screenings to monitor her health proactively. Without this genetic information, she and her healthcare team would not have known about this crucial preventive measure.
Expanding genetic testing beyond traditional familial identification methods is crucial, considering smaller family sizes in current generations. Laura Palma, a certified genetic counselor at McGill University Health Centre, emphasizes the importance of broadening access to genetic testing to reach more high-risk individuals. Understanding how participants utilize the genetic information, potentially altering lifestyle habits, remains a key area of interest.
While the genomic testing and subsequent care come with costs, assessing the overall cost-effectiveness and feasibility within the Canadian healthcare system is essential. Experts like Jenna Scott from the University of British Columbia acknowledge the positive impact of such projects but raise questions regarding scalability and addressing diverse cultural needs.
The research team plans to share the project findings with participants to evaluate the effectiveness of broader genetic screening initiatives. In addition to patients, family members at risk of familial hypercholesterolemia will receive counseling, surveillance, and personalized treatments as needed. Helix, a biotechnology company based in California, collaborates on this project, with a focus on ensuring strict privacy protection measures as approved by the hospital’s research ethics board.